Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Burning Rock Biotech Limited specializes in next-generation sequencing-based precision oncology diagnostics. The company has commercialized multiple NGS panels for both tissue and liquid biopsies targeting a range of solid tumors. In October 2024, it received marketing approval from the Chinese National Medical Products Administration (NMPA) for its first co-developed NGS-based companion diagnostic assay for lung cancer. The company continues to expand its portfolio with a focus on early detection and therapy selection in oncology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Burning Rock Biotech Limited.